NUR-SULTAN – Kazakhstan is building a plant in the south of the country to produce COVID-19 vaccines and other immunobiological drugs from the first quarter of 2021, the Government of the Central Asian country announced on Tuesday.
Deputy Prime Minister Yeraly Tugzhanov was briefed on Tuesday on construction progress at the Biosafety Research Institute plant in Gvardeyskiy, in the southern province of Jambyl, near the border with Kyrgyzstan.
The biopharmaceutical factory is to start operating in the first quarter of 2021 to produce between 30 and 60 million doses of immunobiological drugs per year, according to the Interdepartmental Commission heading the fight against the spread of COVID-19.
The plant will produce vaccines against coronavirus, influenza, tuberculosis, brucellosis, bovine nodular dermatitis and other infectious diseases.
Earlier this month, the presidents of Kazakhstan and Russia, Kassym-Jomart Tokayev and Vladimir Putin, discussed joint cooperation to stop the coronavirus pandemic and the possibility of the production of Russian vaccines in Kazakh territory.
The Government of Kazakhstan has already started negotiations to attract investment to this project.
In the Central Asian country, 126,860 cases of coronavirus and 1,996 deaths have been detected since the start of the pandemic.